Cardiolynx Receives Patent on Improved Angina Pectoris Drug

| Print |
Thursday, 20 September 2012 09:00 (UTC + 2)

cardiolynx_logo

Basel, Switzerland, September 20, 2012 / B3C newswire / - Cardiolynx Ltd., specializing in the development of improved cardio-metabolic therapies, announces that the European Patent Office (EPO) has granted a patent covering a new chemical entity, CLC-1280, developed using Cardiolynx’ nitric oxide technology. CLC-1280 is based on an established late lifecycle product and is being developed for treating hypertensive patients with angina pectoris.

The Cardiolynx technology employs specific vasodilating chemical linkers as grafts onto or in combination with established cardiovascular drugs resulting in a dual mode of action: the original mode of action of the established product plus the synergistic vasodilative mode.

Dr. Dirk Sartor, CEO of Cardiolynx, commented: “CLC-1280 is active in preclinical models of vasodilatation and has the potential to reduce blood pressure and prevent or reduce angina pectoris thus improving the standard care of this chronic and debilitating condition. The new patent strengthens Cardiolynx’s intellectual property portfolio which includes four patent families with pending applications worldwide.” 

Cardiolynx recently presented preclinical data of CLC-1280 at the 5th Annual European Life Sciences Forum in Zurich, March 6-7, 2012, Switzerland. The data demonstrated the vasodilatory efficacy of CLC-1280 in two animal models (1).

 
About angina pectoris
Angina pectoris (AP, thoracic pain due to coronary artery disease) is the third largest indication in the cardiovascular market and the leading symptom of patients with coronary artery disease (CAD). AP affects 10-20 % of people over age of 65. Inherent limitations of the currently available drugs for AP include development of drug tolerance, side effects and unsatisfactory efficacy. Therefore, there is a clear unmet medical need for new drugs which can overcome these limitations and have a superior benefit/risk profile. In patients suffering from angina pectoris (AP) due to coronary heart disease Cardiolynx’ proprietary technology is expected to provide coronary vasodilatation and improved blood pressure control, thus preventing or reducing AP and improving exercise tolerability. In initial preclinical experiments, Cardiolynx’ compounds demonstrated strong evidence for increased efficacy as compared to the basic molecules. In addition, they showed no development of nitrate tolerance, which is a classical undesired effect of conventional anti-angina drugs, reducing their efficacy. Global drug sales for angina pectoris will reach an estimated $1.3 billion in 2012. 

About Cardiolynx
Cardiolynx ltd. is a biotechnology company focused developing innovative cardio-metabolic therapies. Cardiolynx’ vision is to develop superior medical compounds aimed at maximizing the potential for late lifecycle management of established products. The current focus is on three indications with solid growth potential resulting from the increasing prevalence of cardiovascular diseases in the aging population. Cardiolynx has successfully filed its specific intellectual property for patent protection and is developing a series of drug candidates across the cardio-metabolic disease areas. Cardiolynx is financed by ErfindungsVerwertung AG EVA, Basel and private investors

 
Contact

Dr. Dirk Sartor
Cardiolynx Ltd.
phone +49 152 33614996
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

(1)  Knorr M et al.: Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol. Pharmacology 2012; 90: 193-204, online DOI: 10, 1159/000339861